Literature DB >> 35478146

Enchondromas of the Hand: Curettage With Autogenous Bone vs. Bioactive Glass S53P4 for Void Augmentation.

Nina Lindfors1, Elias Kukkonen1, Antti Stenroos2, Panu H Nordback1, Turkka Anttila1, Samuli Aspinen3.   

Abstract

Background/Aim Enchondroma is the most common primary bone tumour of the hand. When surgery is indicated, curettage with or without void augmentation has been described. However, only few comparative studies exist. The aim of this study was to compare the outcomes of hand enchondromas treated with autologous bone graft (AG) and bioactive glass S53P4 (BAG). PATIENTS AND METHODS: A retrospective comparative analysis was conducted among patients surgically treated for hand enchondromas at a tertiary referral centre during a 17-year period.
RESULTS: A total of 190 patients (116 AG vs. 74 BAG) with 205 enchondromas were included. No statistically significant differences in outcome measures were observed. A reoperation was performed in five patients in the autologous bone-graft group; one patient presented a rare malignant transformation from enchondroma to chondrosarcoma after the primary operation. No reoperations were performed in the BAG group.
CONCLUSION: Although AG is the gold standard for filling bony cavities, bone-graft retrieval can cause complications and postoperative pain. Our results suggest that S53P4 BAG is a safe and effective bone-graft material alternative for filling of enchondroma-evacuated cavities.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Bioactive glass; bone graft; bone tumour; enchondroma

Mesh:

Substances:

Year:  2022        PMID: 35478146      PMCID: PMC9087064          DOI: 10.21873/invivo.12826

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  23 in total

1.  Adjunctive treatment of enchondromas with CO2 laser.

Authors:  D W Giles; S J Miller; G M Rayan
Journal:  Lasers Surg Med       Date:  1999       Impact factor: 4.025

2.  Is the treatment of enchondroma in the hand by simple curettage a rewarding method?

Authors:  P Tordai; M Hoglund; H Lugnegård
Journal:  J Hand Surg Br       Date:  1990-08

3.  The use of bone graft substitutes in large cancellous voids: any specific needs?

Authors:  Omar Faour; Rozalia Dimitriou; Charlotte A Cousins; Peter V Giannoudis
Journal:  Injury       Date:  2011-07-02       Impact factor: 2.586

4.  Bioactive glass S53P4 in frontal sinus obliteration: a long-term clinical experience.

Authors:  Matti Peltola; Kalle Aitasalo; Jouko Suonpää; Matti Varpula; Antti Yli-Urpo
Journal:  Head Neck       Date:  2006-09       Impact factor: 3.147

5.  Treatment outcome of enchondroma by simple curettage without augmentation.

Authors:  Takeshi Morii; Kazuo Mochizuki; Takashi Tajima; Kazuhiko Satomi
Journal:  J Orthop Sci       Date:  2010-02-12       Impact factor: 1.601

Review 6.  Enchondroma of the Hand: Evaluation and Management.

Authors:  John D Lubahn; Abdo Bachoura
Journal:  J Am Acad Orthop Surg       Date:  2016-09       Impact factor: 3.020

7.  The surgical management of hand enchondroma without postcurettage void augmentation: authors' experience and a systematic review.

Authors:  Abdo Bachoura; Ian S Rice; Andrew R Lubahn; John D Lubahn
Journal:  Hand (N Y)       Date:  2015-09

8.  S53P4 bioactive glass scaffolds induce BMP expression and integrative bone formation in a critical-sized diaphysis defect treated with a single-staged induced membrane technique.

Authors:  E Eriksson; R Björkenheim; G Strömberg; M Ainola; P Uppstu; L Aalto-Setälä; V-M Leino; L Hupa; J Pajarinen; N C Lindfors
Journal:  Acta Biomater       Date:  2021-03-25       Impact factor: 8.947

9.  Cost-Effectiveness Study of One-Stage Treatment of Chronic Osteomyelitis with Bioactive Glass S53P4.

Authors:  Jan Geurts; Tom van Vugt; Eline Thijssen; Jacobus J Arts
Journal:  Materials (Basel)       Date:  2019-09-30       Impact factor: 3.623

10.  Sintered S53P4 bioactive glass scaffolds have anti-inflammatory properties and stimulate osteogenesis in vitro

Authors:  R Björkenheim; E Jämsen; E Eriksson; P Uppstu; L Aalto-Setälä; L Hupa; K K Eklund; M Ainola; N C Lindfors; J Pajarinen
Journal:  Eur Cell Mater       Date:  2021-01-03       Impact factor: 3.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.